Literature DB >> 21563324

Measuring calcitonin in washout of the needle in patients undergoing fine needle aspiration with suspicious medullary thyroid cancer.

P Trimboli1, F Rossi, R Baldelli, O Laurenti, G Nigri, C Ventura, M Appetecchia, D Attanasio, F Romanelli, L Guidobaldi, M Guarino, A Crescenzi, S Valabrega.   

Abstract

Calcitonin measurement in washout of the needle after aspiration (WO-Ct) has been rarely evaluated. Here we analyzed the role of WO-Ct in a series of subjects who underwent fine needle aspiration (FNA) with suspicious medullary thyroid cancer (MTC). Twenty-one patients referred following elevated serum calcitonin (S-Ct) or suspicious MTC by cytology. All patients underwent re-evaluation of S-Ct, FNA, and measurement of WO-Ct. S-Ct and WO-Ct were assessed by chemiluminescence assay (IMMULITE 2000, Diagnostic Products Corporation, USA). S-Ct showed elevated value in six subjects (mean 368.8 ± 373.9 pg/ml), of which three cases were cytologically classified as Class 5. WO-Ct obtained in this group (304.0 ± 309.3 pg/ml) was no different from S-Ct. After surgery MTC was confirmed in all patients. In the other 15 patients MTC was excluded by cytology or histology. Two subjects had moderately skewed S-Ct with nonmedullary histology. In the remaining 13 patients S-Ct resulted normal (6.2 ± 5.6 pg/ml) and WO-Ct low (2.9 ± 2.2 pg/ml). Significant (two-tailed P < 0.05, r(2) = 0.27, 95% confidence interval = 0.017-0.81) correlation was found between S-Ct and WO-Ct in nonmedullary patients but not in MTC patients. This study showed that WO-Ct can play a role in diagnosing primary and metastatic MTC. The procedure is easy, cost effective, and should be used in patients undergoing FNA with elevated S-Ct. Further studies and guidelines for the method are needed to use this technique in clinical routine. Until this any institute should use itself cut-off.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563324     DOI: 10.1002/dc.21731

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  4 in total

1.  Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests.

Authors:  Cléber P Camacho; Susan C Lindsey; Maria Clara C Melo; Ji H Yang; Fausto Germano-Neto; Flávia de O F Valente; Thiago R N Lima; Rosa Paula M Biscolla; José G H Vieira; Janete M Cerutti; Magnus R Dias-da-Silva; Rui M B Maciel
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

2.  Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study.

Authors:  Pierpaolo Trimboli; Luca Giovanella; Stefano Valabrega; Massimiliano Andrioli; Roberto Baldelli; Nadia Cremonini; Fabio Rossi; Leo Guidobaldi; Agnese Barnabei; Francesca Rota; Antonella Paoloni; Laura Rizza; Giorgio Fattorini; Maurizio Latini; Claudio Ventura; Paolo Falasca; Fabio Orlandi; Anna Crescenzi; Ferdinando D'Ambrosio; Vito Cantisani; Francesco Romanelli; Roberto Negro; Enrico Saggiorato; Marialuisa Appetecchia
Journal:  J Exp Clin Cancer Res       Date:  2014-10-25

3.  The application value of modified thyroid imaging report and data system in diagnosing medullary thyroid carcinoma.

Authors:  Jialin Zhu; Xing Li; Xi Wei; Xueling Yang; Jing Zhao; Sheng Zhang; Zhi Guo
Journal:  Cancer Med       Date:  2019-05-09       Impact factor: 4.452

4.  Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma.

Authors:  C de Crea; M Raffaelli; D Maccora; C Carrozza; G Canu; G Fadda; R Bellantone; C P Lombardi
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-12       Impact factor: 2.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.